Skip to main content

Advertisement

Table 1 Genotype frequencies of polymorphisms in NOD1, NOD2, TLR2, TLR4 and TLR9 and endometrial cancer risk

From: Toll-Like Receptor (TLR) and Nucleosome-binding Oligomerization Domain (NOD) gene polymorphisms and endometrial cancer risk

Polymorphism Genotypes Cases n (%) Controls n (%) χ2 OR (95% CI) and p value
  TT 119 (62.3) 176 (60.5)   
NOD1 (rs2075822) TC 62 (32.5) 105 (36.1)   1.188
  CC 10 (5.2) 10 (3.4) p = 0.497 (0.774-1.823) p = 0.432
  TC+CC 72 (37.7) 115 (39.5)   
  AA 104 (54.5) 152 (52.2)   
NOD1 (rs2907749) AG 68 (35.6) 118 (40.6)   1.156
  GG 19 (9.9) 21 (7.2) p = 0.392 (0.759-1.761) p = 0.499
  AG+GG 87 (45.5) 139 (47.8)   
  CC 114 (59.7) 168 (57.7)   
NOD1 (rs2907748) CT 64 (33.5) 110 (37.8)   1.156
  TT 13 (6.8) 13 (4.5) p = 0.400 (0.755-1.769) p = 0.505
  CT+TT 77 (40.3) 123 (42.3)   
  CC 182 (95.3) 282 (96.9)   1.549
NOD2 (rs5743260) CT 9 (4.7) 9 (3.1) p = 0.359 (0.604-3.977) p = 0.363
  TT 0 (0.0) 0 (0.0)   
  CC 178 (93.2) 263 (90.4)   0.928
NOD2 (rs2066844) CT 13 (6.8) 28 (9.6) p = 0.278 (0.407-2.116) p = 0.859
  TT 0 (0.0) 0 (0.0)   
  GG 187 (97.9) 282 (96.9)   0.636
NOD2 (rs2066845) GC 4 (2.1) 9 (3.1) p = 0.508 (0.143-2.835) p = 0.553
  CC 0 (0.0) 0 (0.0)   
  GG 177 (92.7) 275 (94.5)   1.190
TLR2 (rs5743708) GA 14 (7.3) 16 (5.5) p = 0.416 (0.501-2.826) p = 0.694
  AA 0 (0.0) 0 (0.0)   
  AA 163 (85.3) 258 (88.7)   
TLR4 (rs4986790) AG 25 (13.1) 31 (10.6)   1.098
  GG 3 (1.6) 2 (0.7) p = 0.449 (0.573-2.101) p = 0.778
  AG+GG 28 (14.7) 33 (11.3)   
  TT 85 (44.5) 116 (39.9)   
TLR9 (rs5743836) TC 79 (41.4) 128 (44.0)   0.781
  CC 27 (14.1) 47 (16.1) p = 0.581 (0.511-1.195) p = 0.255
  TC+CC 106 (55.5) 175 (60.1)   
  TT 138 (72.25) 187 (64.3)   
TLR9 (rs187084) TC 49 (25.65) 88 (30.2)   0.675
  CC 4 (2.1) 16 (5.5) p = 0.076 (0.428-1.064) p = 0.091
  TC+CC 53 (27.75) 104 (35.7)   
  1. NB: Χ2 - Wild-type genotype versus heterozygous genotype versus homozygous variant genotype. Odds ratios for polymorphisms in NOD1, TLR4 and TLR9 were calculated as follows: Wild Type genotype compared to combination of heterozygous and homozygous variant genotypes. Odds ratios for polymorphisms in NOD2 and TLR2 were calculated as follows: Wild Type genotype compared to heterozygous genotype. All Odds Ratios were adjusted for age, BMI, diabetes, HBP, history of cancer, HT, smoking and alcohol use.